Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped up before the market opened on Tuesday. The stock had previously closed at $14.35, but opened at $15.13. Astellas Pharma shares last traded at $14.44, with a volume of 1,259 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

Astellas Pharma Trading Up 0.9%

The company has a market capitalization of $26.20 billion, a PE ratio of 11.02 and a beta of 0.08. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.93 and a current ratio of 1.20. The business has a fifty day moving average price of $14.74 and a 200 day moving average price of $14.48.

About Astellas Pharma

Astellas Pharma Inc is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation.